For example, a small number of early-phase paediatric trials are recruiting children whose tumours harbour genetic alterations including ALK genomic alterations (mutations, amplifications or translocations) that can be treated with ALK inhibitors and BRAF V600 mutant tumours that can be treated with BRAF or MEK inhibitors. This evidence concerns the gene MAP2K7 and neoplasm.